

CONTINUED FROM PAGE 7					
3	Condoms		1 Condom	10.14	1331 (E) 25.03.2021
4	Dapsone	Tablet 50 mg	1 Tablet	0.26	1331 (E) 25.03.2021
5	Etoposide	Capsules 100 mg	1 Capsule	67.22	1331 (E) 25.03.2021
6	Framycetin Sulphate	Cream 0.50%	1 GM	0.97	1331 (E) 25.03.2021
7	Isoniazid	Syrup 100 mg/5ml	1 ML	0.29	1331 (E) 25.03.2021
8	Medroxy Progesterone Acetate	Tablet 5mg	1 Tablet	3.32	1331 (E) 25.03.2021
9	Rifampicin	Tablet 450mg	1 Tablet	4.92	1331 (E) 25.03.2021

Note:

(a) The ceiling prices are applicable with effect from 01.04.2022 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 10.76607% for the year 2021 over 2020).

(b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services taxes as applicable.

(c) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 10.76607% for year 2021 over 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

(d) The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(e) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(f) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(g) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(h) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(i) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(j) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

(l) For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation

(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

ORDER

New Delhi, the 30th March, 2022

S.O. 1505(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3937(E) dated 23.09.2021 and S.O. 5426(E) dated 28.12.2021, in so far as they relate to Metronidazole Injection IP (0.5% w/v) 500mg/100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels mentioned in the Table A herein below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2021 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE A

Price Revision as per Annual Wholesale Price Index (WPI) @ 10.76607% increase.

Sl. No.	Medicines	Dosage form and Strength	Unit	Ceiling price (wef 01.04.2022 with WPI @ 10.76607%)
(1)	(2)	(3)	(4)	(5)
1	Mannitol	Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features	Per ml	0.382

TABLE 'B'

Sl. No.	Name of Manufacturer
(1)	(2)
1	M/s Otsuka Pharmaceutical India Private Ltd.
2	M/s Denis Chem Lab Ltd.
3	M/s Rusoma Laboratories Pvt. Ltd.

Note:

(a) The ceiling prices are applicable with effect from 01.04.2022 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 10.76607% for the year 2021 over 2020).

(b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 10.76607% for year 2021 over 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

(d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(e) Any other manufacturer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels shall apply to NPPA for separate ceiling price approval.

(f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation.

(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

ORDER

New Delhi, the 30th March, 2022

S.O. 1506(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3937(E) dated 23.09.2021 and S.O. 5428(E) dated 28.12.2021, in so far as they relate to Dextrose (Glucose) Injection (25% w/v) 500mg/100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels mentioned in the Table A herein below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2021 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE A

Price Revision as per Annual Wholesale Price Index (WPI) @ 10.76607% increase.

Sl. No.	Medicines	Dosage form and Strength	Unit	Ceiling price (wef 01.04.2022 with WPI @ 10.76607%)
(1)	(2)	(3)	(4)	(5)
1	Dextrose (Glucose)	Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features	Per ml	0.2165

TABLE 'B'

Sl. No.	Name of Manufacturer
(1)	(2)
1	M/s. Otsuka Pharmaceutical India Private Ltd.
2	M/s. Denis Chem Lab Ltd.
3	M/s. Rusoma Laboratories Pvt. Ltd.

Note:

a. The ceiling prices are applicable with effect from 01.04.2022 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 10.76607% for the year 2021 over 2020).

b. The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

c. The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 10.76607% for year 2021 over 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

d. The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

e. Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels shall apply to NPPA for separate ceiling price approval.

f. For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation

g. The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

h. As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

i. Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

j. The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of